genes and the environment in cancer causation joseph f. fraumeni, jr., m.d
DESCRIPTION
Genes and the Environment in Cancer Causation Joseph F. Fraumeni, Jr., M.D. Third Annual Alan S. Rabson Award Lecture for Intramural Research. National Cancer Institute January 9, 2007. - PowerPoint PPT PresentationTRANSCRIPT
Genes and the Environmentin Cancer Causation
Joseph F. Fraumeni, Jr., M.D.
National Cancer Institute
January 9, 2007
Third Annual Alan S. Rabson Award Lecture for Intramural Research
A distinguished NIH couple, Alan Rabson (Deputy Director of NCI) and Ruth Kirschstein
(former Acting Director of NIH)
Early Days at the National Cancer Institute
Categories of Cancer Causation
Environment- +
Gen
es+
- Spontaneous
Microbes – 1960s Chemicals – 1970s Lifestyle – 1980s
Hereditary syndromes Low-penetrant variants
Interactions
International Variation in Cancer Incidence
Type of Cancer H/L Highest Rates Lowest Rates
Melanoma 155 Australia Japan
Nasopharynx 100 Hong Kong U.K.
Prostate 70 U.S. (Black) China
Liver 50 China Canada
Cervix uteri 28 Brazil Israel
Stomach 22 Japan Kuwait
Lung 19 U.S. (Black) India
Colon 19 U.S. (White) India
Bladder 16 Switzerland India
Pancreas 11 U.S. (Black) India
Ovary 8 N.Z. (Maori) Kuwait
Breast 7 Hawaii (Hawaiian) Israel (Non-Jews)
Leukemia 5 Canada India
RRs of Breast Cancer in Asian-American Women by Migration History
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
E // 4E rural - E <8 y in W
E // 4Eurban - E<8 y in W
E // 4E rural - E 8+ y in W
E // 4Eurban - E8+ y in W
W // 4E W//1-2W W//3-4W
Re
lati
ve
Ris
ks
Ziegler, R. et al. JNCI 1993; 85: 1819-27
Estimated Annual Percent Increase in Cancer Incidence
SEER 1992-2001
WM WF BM BF
Liver 3.9 5.0 4.8 2.2
Melanoma 3.2 3.2 2.2 -3.4
Thyroid 2.8 4.8 0.8 3.8
Kidney 1.4 1.4 1.9 2.8
Testis 1.3 - 6.4 -
NHL -0.5 0.8 -1.5 2.9
Esophagus 1.9 -0.2 -5.8 -4.1
Esophageal Cancer, 1973-1998 (Males)
Squamous Cell CarcinomaBlack Males
Squamous Cell CarcinomaWhite Males
AdenocarcinomaBlack Males
AdenocarcinomaWhite Males
73-74 78-80 84-86 90-92 96-98
1
10
Year of Diagnosis
Rate per 100,000
0.1
Esophageal Cancer, 1973-1998 (Males)
Squamous Cell CarcinomaBlack Males
Squamous Cell CarcinomaWhite Males
AdenocarcinomaBlack Males
AdenocarcinomaWhite Males
73-74 78-80 84-86 90-92 96-98
1
10
Year of Diagnosis
Rate per 100,000
0.1
Squamous Cell CarcinomaBlack Males
Squamous Cell CarcinomaWhite Males
AdenocarcinomaBlack Males
AdenocarcinomaWhite Males
73-74 78-80 84-86 90-92 96-98
1
10
Year of Diagnosis
Rate per 100,000
0.1
Copper Smelter, Montana
Indoor Air Pollution in China
The Causes of Cancer
• Tobacco +++++• Alcohol ++?• Nutrition, including energy balance +++?• Infection and inflammation ++?• Occupational hazards +?• Environmental pollution +?• Pharmaceuticals, including hormones +?• Ionizing and UV radiation +?• Genetic susceptibility ++???
Note: About 50% of all cancer appears related to modifiable risk factors.
Alfred G. Knudson and Two-hit Model for Retinoblastoma
Proc Natl Acad Sci USA 1971; 68: 820-3
Child with Congenital Aniridia
Li-Fraumeni Syndrome_________________________________
• Dominantly inherited
• Striking variety of early-onset tumors
• Predisposition to second primaries
• Germline mutations of p53
Cloned Familial Tumor Suppressor Genes
Retinoblastoma RB1 13q14 1986
Wilms’ tumor WT1 11p13 1990
Li-Fraumeni syndrome p53 17p13 1990
Neurofibromatosis 1 NF1 17q11 1990
Neurofibromatosis 2 NF2 22q12 1993
von Hippel-Lindau syndrome VHL 3p25 1993
Familial melanoma 1 p16 9p211994
Familial breast cancer 1 BRCA1 17q21 1994
Familial breast cancer 2 BRCA2 13q12 1995
Basal cell nevus syndrome PTC 9q22 1996
0
10
20
30
40
0 10 20 30 40 50
Survival (Years)
Pe
rce
nt
Cu
mu
lati
ve
In
cid
en
ce
Radiotherapy No Radiotherapy
Cumulative Incidence of Second Cancer After Hereditary Retinoblastoma
Susceptibility (Modifier) Genes*
Function ExamplesBehavior OPRMI, LEP
Metabolism ALDH2, NAT2, MTHFR
Hormones COMT, SRD5A2
Growth Factors IGF1, GMCSF
Cell Cycle CHEK2
DNA Repair XRCC1, XRCC3
Apoptosis FAS, CASP8
Telomerase TERT, DKC1
Angiogenesis VEGF, CD14
Immune Regulation CCR5, TNF, IL8
*Role of carcinogens or anti-carcinogens may be inferred by knowing the substrate or pathway of the gene variant.
Moving Toward Large-scale Studies:International Consortia
• Multicenter partnerships that strategically and cost-efficiently utilize separately funded epidemiologic studies with biospecimen collections.
• Cohort, case-control, and family-based consortia that maximize power of genomic and other emerging technologies.
• Replication strategies: Provides rapid confirmation of positive or negative findings from independent datasets.
• Pooling strategies: Combines datasets for statistical power to identify risks from gene variants, exposures, and interactions.
InterLymph (18,000 Cases) International Lymphoma Epidemiology Consortium
Participating Centers
IL1B-511 Variant TNF G-308A Variant
Rothman, et al. Lancet Oncol 2006; 7: 27-38
NCI Consortium of CohortsExploiting the Molecular Revolution for Cancer Discovery and Pre-emption
Follow-up Study #1 3500 cases/3500 controls
Follow-up Study #23500 cases/3500 controls
Fine Mapping
Initial Study1150 cases/1150 controls
~28,000 SNPs
at least 1,500SNPs
30 ±20loci
540,000 Tag SNPs
General Strategy for Prostate & Breast CancerGenome-wide Association Studies
Epidemiology During the Molecular Revolution
• Move with greater speed and force to identify genetic/environmental determinants in cancer induction and progression.
• Probe into causal pathways and mechanisms as possible targets for intervention.
• Foster platforms and strategies of large-scale studies, including consortial initiatives.
• Encourage multidisciplinary research to galvanize discovery and translation to clinical practice and public health.
DCEG Senior Advisory Group Retreat 2006
Robert Warwick Miller, M.D.1921 – 2006